These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15791469)

  • 1. Combination of surgery and immunotherapy in metastatic renal cell carcinoma.
    Mickisch GH; Mattes RH
    World J Urol; 2005 Jul; 23(3):191-5. PubMed ID: 15791469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality treatment of metastatic renal cell carcinoma.
    Mickisch GH
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urologic approaches to metastatic renal cell carcinoma.
    Mickisch GH
    Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view.
    Mickisch GH
    Urol Int; 1999; 63(1):16-21. PubMed ID: 10592485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of tumor nephrectomy in metastatic renal cell carcinoma].
    Scheepe JR; Mickisch GH
    Urologe A; 2002 May; 41(3):221-4. PubMed ID: 12132270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of nephrectomy for malignant disease.
    Mickisch GH
    BJU Int; 2002 Mar; 89(5):488-95. PubMed ID: 11929471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
    Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
    Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
    Bex A; Powles T
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
    Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.